News
CG’s IPO launches as NASDAQ’s first biotech of 2024
CG Oncology, Inc. Rings the Opening Bell
Developing Oncolytic Viruses to Fight Cancer with Arthur Kuan
Cold Genesys' Arthur Kuan Is Helping To Reinvent The Way We Approach Cancer | Forbes
News
2024-12-06
SUO-CTC and CG Oncology Announce the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award
2024-08-30
CG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
2024-01-30
CG Oncology Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
2024-01-24
Biotech's 2024 IPO season kicks off with heavy demand for CG Oncology in $380M listing
2023-12-05
CG Oncology Receives Both FDA Fast Track and Breakthrough Therapy Designation for Cretostimogene Grenadenorepvec in High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2023-11-14
CG Oncology Announces Presentation of the First Phase 3 Monotherapy Data for Cretostimogene Grenadenorepvec in BCG-Unresponsive NMIBC Patients at SUO 2023
2023-07-24
CG Oncology Completes Patient Enrollment in BOND-003 Phase 3 Monotherapy Study with Cretostimogene Grenadenorepvec in BCG-Unresponsive High-Risk NMIBC
2023-05-01
CG Oncology Announces New Phase 2 Data with Cretostimogene Grenadenorepvec (CG0070) in Combination with KEYTRUDA® (pembrolizumab) in BCG-Unresponsive NMIBC
2022-11-15
Can an oncolytic virus therapy challenge the standard of care in bladder cancer? CG Oncology has $120M to find out
2022-11-15
CG Oncology Raises $120 Million in Oversubscribed Series E Financing to Advance Clinical-Stage Urologic Oncology Pipeline
2022-11-15
Venture Capitalists Back CG Oncology’s Search for New Bladder Cancer Treatment: CG Oncology’s immunotherapy might help patients avoid bladder-removal surgery
2022-11-10
CG Oncology spotlights oncolytic virus combo data ahead of full readout due next year
2022-11-10
CG Oncology Presents New Phase 2 Data With CG0070 in Combination With KEYTRUDA® (pembrolizumab) in Non-Muscle Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guérin
2021-12-20
CG Oncology Announces First Patient Dosed in Japan in Phase 3 Monotherapy Study of CG0070 in Non-Muscle-Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin
2021-11-13
CG Oncology Presents Preliminary Phase 2 Data with CG0070 in Combination with KEYTRUDA® (pembrolizumab) in Non-Muscle-Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin
2021-09-22
CG Oncology and Roche to Collaborate on Clinical Trial of Oncolytic Immunotherapy CG0070 as Part of Novel Combination for Various Solid Tumor Indications
2021-09-09
CG Oncology Announces Clinical Trial Collaboration with Bristol Myers Squibb to Evaluate Oncolytic Immunotherapy CG0070 in Combination with OPDIVO® (nivolumab) in Metastatic Urothelial Cancer
2020-12-09
CG Oncology Announces First Patient Dosed in Phase 2 Clinical Trial of CG0070, an Oncolytic Immunotherapy, in Combination with KEYTRUDA® (pembrolizumab) for Non-Muscle-Invasive Bladder Cancer
2020-11-12
CG Oncology Announces First Patient Dosed in Phase 1b Study of Oncolytic Immunotherapy CG0070 in Combination with OPDIVO® (nivolumab) in Muscle-Invasive Bladder Cancer
2020-03-26
CG Oncology Announces License and Commercialization Agreement with Kissei Pharmaceutical Co., Ltd. for CG0070 in Japan and Other Asian Countries
2018-11-28
Cold Genesys Announces Clinical Trial Collaboration to Evaluate the Combination of CG0070 and KEYTRUDA® (pembrolizumab) in Bladder Cancer
2017-05-15
Cold Genesys Announces Clinical Results at American Urological Association (AUA) Annual Meeting 2017
2017-04-25